Results 181 to 190 of about 94,231 (226)

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Advances and challenges in experimental models for Epstein–Barr virus research

open access: yesmLife, EarlyView.
Abstract Epstein–Barr virus (EBV), the first identified human oncovirus, is a ubiquitous γ‐herpesvirus etiologically linked to diverse malignancies, lymphoproliferative disorders, and autoimmune diseases. Experimental models are pivotal for unraveling the infection and pathogenesis mechanisms, life cycle regulation, as well as development and ...
Gulimire Wufuer   +5 more
wiley   +1 more source

Endoscopic Treatment for Esophagogastric Variceal Bleeding in Patients With Acute‐on‐Chronic Liver Failure: An Observational Study

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
In patients with acute‐on‐chronic liver failure (ACLF), esophagogastric variceal bleeding (EGVB) represents a critical complication associated with high short‐term mortality. This study evaluated the efficacy of endoscopic treatment in this specific population and identified prognostic factors associated with 6‐week rebleeding and mortality.
Yanan Sun   +7 more
wiley   +1 more source

Current and Future Landscape of Hepatocellular Carcinoma Treatment. [PDF]

open access: yesOncol Res
Zerehpoosh S   +6 more
europepmc   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao   +4 more
wiley   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen   +5 more
wiley   +1 more source

Nanoparticle approaches for hepatitis therapy and clinical translation. [PDF]

open access: yesDiscov Nano
Mohamed NA   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy